• 1
    Fischer B., Keates A., Bühringer G., Reimer J., Rehm J. Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world? Addiction 2014; 109: 177181.
  • 2
    Morbidity and Mortality Weekly Report. Overdose deaths involving prescription opioids among Medicaid enrollees – Washington, 2004–2007. Morb Mortal Wkly Rep 2009; 58: 11711175.
  • 3
    Rintoul A. C., Dobbin M. D. H., Drummer O. H., Ozanne-Smith J. Increasing deaths involving oxycodone, Victoria, Australia, 2000–09. Inj Prev 2011; 17: 254259.
  • 4
    Olshansky S. J., Antonucci T., Berkman L., Binstock R. H., Boersch-Supan A., Cacioppo J. T. et al. Differences in life expectancy due to race and educational differences are widening, and many may not catch up. Health Aff 2012; 31: 18031813.
  • 5
    Feldman L., Williams K. S., Coates J., Knox M. Awareness and utilization of a prescription monitoring program among physicians. J Pain Palliat Care Pharmacother 2011; 25: 313317.
  • 6
    Krebs E. E., Ramsey D. C., Miloshoff J. M., Bair M. J. Primary care monitoring of long-term opioid therapy among veterans with chronic pain. Pain Med 2011; 12: 740746.
  • 7
    Britt H., Miller G. C., Charles J., Henderson J., Bayram C., Pan Y. et al. General Practice Activity in Australia 2010–11, in Bettering the Evaluation and Care of Health. Sydney: Sydney University Press; 2011.
  • 8
    Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health 2009; 99: 221227.
  • 9
    Jovey R. D., Ennis J., Gardner-Nix J., Goldman B., Hays H., Lynch M. et al. Use of opioid analgesics for the treatment of chronic noncancer pain—a consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Res Manag 2003; 8: 3A28A.
  • 10
    Persaud N. Questionable content of an industry-supported medical school lecture series: a case study. J Med Ethics 2013; doi:10.1136/medethics-2013-101343.
  • 11
    BRR Media. Phosphagenics Limited—ASX Small to Mid Caps Conference in Singapore and Hong Kong. 2011. Available at: (accessed 18 June 2013) (Archived at on 17 June 2013).
  • 12
    Jahiel R. I., Babor T. F. Industrial epidemics, public health advocacy and the alcohol industry: lessons from other fields. Addiction 2007; 102: 13351339.
  • 13
    Pearce N. The ecological fallacy strikes back. J Epidemiol Commun Health 2000; 54: 326327.
  • 14
    Fischer B., Jones W., Rehm J. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005–2009. Pharmacoepidemiol Drug Saf 2013; 22: 438442.
  • 15
    Burghardt L. C., Ayers J. W., Brownstein J. S., Bronstein A. C., Ewald M. B., Bourgeois F. T. Adult prescription drug use and pediatric medication exposures and poisonings. Pediatrics 2013; 132: 110.
  • 16
    Dowell D., Kunins H. V., Farley T. A. Opioid analgesics—risky drugs, not risky patients. JAMA 2013; 309: 22192220.
  • 17
    Rose G., Day S. The population mean predicts the number of deviant individuals. BMJ 1990; 301: 10311034.
  • 18
    Franklin G. M., Mai J., Turner J., Sullivan M., Wickizer T., Fulton-Kehoe D. Bending the prescription opioid dosing and mortality curves: impact of the Washington State opioid dosing guideline. Am J Ind Med 2011; 55: 325331.
  • 19
    Edlund M. J., Martin B. C., Fan M., Braden J. B., Devries A., Sullivan M. D. An analysis of heavy utilizers of opioids for chronic non-cancer pain in the TROUP Study. J Pain Symptom Manage 2010; 40: 279289.